Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stock-based Compensation (Tables)

Stock-based Compensation (Tables)

9 Months Ended

Sep. 30, 2017

Schedule of stock-based compensation expense related to all of the entity's share-based awards

Total stock-based compensation expense related to all of our share-based payments that we recognized for the three and nine months ended September 30, 2017 and 2016 were as follows (in thousands):


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2017		2016		2017		2016
General and administrative	$	591	$	572	$	1,950	$	1,921
Research and development		282		643		978		2,746
Restructuring charges		—		499		—		499
Total stock-based compensation expense	$	873	$	1,714	$	2,928	$	5,166

Summary of weighted-average assumptions relating to options granted pursuant to equity incentive plans


	Three Months Ended			Nine Months Ended
	September 30,			September 30,
	2017		2016	2017		2016
Risk-free interest rate	2.1	%	—	2.2	%	1.7	%
Expected term (in years)	6.2		—	6.7		6.4
Dividend yield	0.0	%	—	0.0	%	0.0	%
Expected volatility	64.4	%	—	63.2	%	63.3	%

Summary of weighted-average assumptions used to calculate fair value of purchase rights granted under Employee Stock Purchase Plan


	Nine Months Ended
	September 30,
	2017		2016
Risk-free interest rate	0.6	%	0.5	%
Expected term (in years)	1.8		1.5
Dividend yield	0.0	%	0.0	%
Expected volatility	64.6	%	63.0	%